Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping

Top Product

Crossing Over: Exchanges in Art and Biotechnologies

Compare prices

  1. 2. Nature's Operating Instructions: The True Biotechnologies (Bioneers Series)
  2. 3. Bodies, Commodities, and Biotechnologies: Death, Mourning, and Scientific Desire in the Realm of Human Organ Transfer (Leonard Hastings Schoff Lectures)
  3. 4. Bodies, Commodities, and Biotechnologies: Death, Mourning, and Scientific Desire in the Realm of Human Organ Transfer (Leonard Hastings Schoff Lectures)
  4. 5. Biotechnologies and International Human Rights (Studies in International Law)

Shopping Categories

  1. 1. Mobile Phones
  2. 2. Digital Cameras
  3. 3. Smartphones
  4. 4. Laptop Computers
  5. 5. Graphics Cards
  6. 6. LCD TVs
  7. 7. LCD Monitors
  8. 8. Fridges
  9. 9. Vacuum Cleaners
  10. 10. Freezers
  11. 11. Washing Machines
  12. 12. Microwaves
  13. 13. Electric Kettles
  14. 14. Dishwashers
  15. 15. Digital Camcorders

Wikio Shopping

  1. 1. Baby & Nursery
  2. 2. Books
  3. 3. Car/Motorbike
  4. 4. CD
  5. 5. Communication
  6. 6. Computers
  7. 7. DVD
  8. 8. Electronics
  9. 9. Entertainment
  10. 10. Fashion & Lingerie
  11. 11. Finance
  12. 12. Gifts & Gadgets
  13. 13. Health & Beauty
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Sport & Fitness
  18. 18. Travel
  19. 19. Video Games

Participate



Biotechnologies



Sort by : relevance - date - popularity
3Vote!

Dendreon Receives FDA Acknowledgement of Complete Response

SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will...

3Vote!

Rothman Research: Rothman Research Completes Market Research on Financial, Healthcare, Utilities and Basic Materials Sectors

NEW DELHI, INDIA (MARKET WIRE) A nominal slip has been seen in the US market. Wall Street closed just below the previous closing. Housing data created panic. As today's market news unfolds Rothman Research begun tracking the following companies MBIA Inc. (NYSE: MBI), Unum Group (NYSE: UNM), Worthington Industries Inc. (NYSE: WOR), Medicis Pharmaceutical Corp. (NYSE: MRX), Terra Industries Inc. (NYSE:...

4Vote!

Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic...

5Vote!

ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR™ In Systemic Lupus Erythematosus

ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE).

3Vote!

ImmunoGen licenses technology to Amgen for $1M

ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.

3Vote!

American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor

BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.

3Vote!

ImmunoGen Nabs $1M From Amgen

Waltham, MA-based ImmunoGen (NASDAQ: IMGN) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen’s technology for linking targeted antibodies to cell-killing agents that make them more potent. ImmunoGen will get $1 million upfront and could receive $34 million worth of milestone payments over time if Amgen is successful [...]

3Vote!

DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel

COPENHAGEN, Nov. 19 /PRNewswire/ -- Danish Prince Joachim inaugurated the DONG Energy and Inbicon cellulosic ethanol plant in Kalundborg, Denmark, on Wednesday, November 18. The facility is one of the world's first and largest 2nd generation ethanol demonstration biorefineries. Genencor's Accellerase enzymes are used in the plant's innovative process for converting straw to fuel. Genencor, a Division...

3Vote!

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company’s TAP Technology

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen –...

3Vote!

The Deal Names Abbott Top Dealmaker for Second Consecutive Year

ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the second consecutive year. The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective strategic use of acquisitions and divestitures since January 2006.

3Vote!

Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low

Notable 52-week Highs on the NYSE: Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal. Donaldson Company Inc. (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today. IMS Health Inc. (NYSE: RX) - reached $21.65 King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting from mixed ZymoGenetics ratings...

7Vote!

Embraer, GE, Azul and Amyris in Renewable Jet Fuel Evaluation Project

Amyris engineers microbes to convert sugar to hydrocarbon fuels. Micrograph of fermentation fluids from production of Amyris Renewable Diesel (Nov 2007). Source: Amyris. Click to enlarge. Embraer, General Electric, and Amyris Biotechnologies, a synthetic biology company focused on developing renewable...

3Vote!

Allergan, Medicis lead drug stocks lower

BOSTON (MarketWatch) -- Allergan Inc. and Medicis Pharmaceutical Corp. led drug stocks lower early Thursday as shares of the dermatology-products makers fell on news that a new bill unveiled by Senate Democrats would levy a 5% excise tax on cosmetic procedures. The NYSE Arca Pharmaceutical Index and the NYSE Arca Biotechnology Index were both down 1.4% at 298.94 and 872.60, respectively. Shares of...

3Vote!

Aware Inc. Introduces AccuRad ImageShare(TM) Platform at RSNA 2009

BEDFORD, Mass., Nov. 19 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE), a global provider of imaging and biometrics software, today announced it will showcase its new AccuRad ImageShare Platform, a standards-based cross-enterprise image sharing platform for health information exchange (HIE), at the RSNA 2009 Scientific Assembly and Annual Meeting. Aware will also participate in the Integrating...

3Vote!

Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)

MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.